
==== Front
Ann Surg Oncol
Ann Surg Oncol
Annals of Surgical Oncology
1068-9265
1534-4681
Springer International Publishing Cham

38907136
15595
10.1245/s10434-024-15595-0
Colorectal Cancer
The Association of Mismatch Repair Status with Microscopically Positive (R1) Margins in Stage III Colorectal Cancer: A Retrospective Cohort Study
http://orcid.org/0000-0003-4218-4648
Smith Henry G. PhD henry.george.smith@regionh.dk

1
Schlesinger Nis H. MD 1
Chiranth Deepthi MD 2
Qvortrup Camilla PhD 3
1 https://ror.org/05bpbnx46 grid.4973.9 0000 0004 0646 7373 Abdominalcenter K, Copenhagen University Hospital – Bispebjerg and Frederiksberg, Copenhagen, Denmark
2 https://ror.org/05bpbnx46 grid.4973.9 0000 0004 0646 7373 Department of Pathology, Copenhagen University Hospital – Rigshospital, Copenhagen, Denmark
3 https://ror.org/05bpbnx46 grid.4973.9 0000 0004 0646 7373 Department of Oncology, Copenhagen University Hospital – Rigshospital, Copenhagen, Denmark
21 6 2024
21 6 2024
2024
31 10 64236431
21 3 2024
28 5 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

There is mounting evidence that microscopically positive (R1) margins in patients with colorectal cancer (CRC) may represent a surrogate for aggressive cancer biology rather than technical failure during surgery. However, whether detectable biological differences exist between CRC with R0 and R1 margins is unknown. We sought to investigate whether mismatch repair (MMR) status differs between Stage III CRC with R0 or R1 margins.

Methods

Patients treated for Stage III CRC from January 1, 2016 to December 31, 2019 were identified by using the Danish Colorectal Cancer Group database. Patients were stratified according to MMR status (proficient [pMMR] vs. deficient [dMMR]) and margin status. Outcomes of interest included the R1 rate according to MMR and overall survival.

Results

A total of 3636 patients were included, of whom 473 (13.0%) had dMMR colorectal cancers. Patients with dMMR cancers were more likely to be elderly, female, and have right-sided cancers. R1 margins were significantly more common in patients with dMMR cancers (20.5% vs. 15.2%, p < 0.001), with the greatest difference seen in the rate of R1 margins related to the primary tumour (8.9% vs. 4.7%) rather than to lymph node metastases (11.6% vs. 10.5%). This association was seen in both right- and left-sided cancers. On multivariable analyses, R1 margins, but not MMR status, were associated with poorer survival, alongside age, pN stage, perineural invasion, and extramural venous invasion.

Conclusions

In patients with Stage III CRC, dMMR status is associated with increased risks of R1 margins following potentially curative surgery, supporting the use of neoadjuvant immunotherapy in this patient group.

Keywords

Colon cancer
Rectum cancer
Mismatch repair status
Microscopically positive resection
Surgery
Copenhagen UniversityOpen access funding provided by Copenhagen University

issue-copyright-statement© Society of Surgical Oncology 2024
==== Body
pmcIntroduction

Microscopically positive (R1) margins are defined as the presence of viable cancer cells ≤1 mm of the surgical margin and may be related to the primary tumor (R1tumor) or lymph node metastases/tumour deposits (R1LNM).1 Regardless of their subtype, R1 margins are associated with poorer oncological outcomes in patients with either colon or rectum cancers.2–8 Despite their recognized importance, there is an ongoing debate about whether R1 margins represent a technical failure at the time of surgery or are in fact a surrogate for more aggressive disease.9–11

Recent studies from our group based on a large cohort of patients with Stage III colorectal cancer have provided several lines of evidence to support the latter argument. In these studies, cancers with R1 margins are more likely to have other adverse pathological features, such as extramural venous invasion compared with cancers with R0 margins.12 Patterns of relapse also seem to differ according to margin status, with patients with either R1 subtype likely to present with a greater metastatic burden, either in terms of the number of lesions or the number of anatomical sites affected.13 Furthermore, the quality of surgical specimens does not appear to differ between cancers with R0 and R1 margins, implying that technical factors may not be a major determinant of margin status.11 The fact that the most common form of relapse in patients with either R1tumor or R1LNM margins was distant recurrence in the absence of local recurrence adds further weight to this argument.13 Finally, adjuvant therapy appears to be less effective in patients with R1 margins, with the increased risks of relapse persisting even after the use of long course chemotherapy.14

Whilst these studies suggest that R1 margins may be a surrogate for more aggressive disease, whether detectable biological differences exist between cancers with R0 and R1 margins remains to be seen. Routine immunohistochemical/molecular analyses, such as those for mismatch repair (MMR) status, offer an opportunity to investigate these potential biological differences.15 Mismatch repair status has a recognized stage-adjusted association with prognosis in patients with colorectal cancer, whereby patients with cancers that have deficient MMR (dMMR) pathways have better survival outcomes.16 Mismatch repair status also has a predictive value in determining the benefit of adjuvant chemotherapy, with little benefit seen in patients with dMMR cancers compared with surgery alone.17,18 However, recent trials of immunotherapy have increased the value of MMR status as a biomarker, as dMMR cancers have been shown to be exquisitely sensitive to immune checkpoint blockade.19–21 Therefore, if an association between R1 margins and dMMR status exists, this would not only add further weight to the argument that margin status reflects cancer biology but also be actionable, because these patients could be treated with immunotherapy.

In this study, we sought to investigate the association between MMR status and R1 margins in patients with Stage III colorectal cancers and to determine the impact of MMR status on survival in these patients.

Methods

This was a retrospective national cohort study and is reported according to STROBE guidelines.22 Patients diagnosed with Union for International Cancer Control (UICC) Stage III colorectal cancer in Denmark between January 1, 2016 and December 12, 2019 were identified from the Danish Colorectal Cancer Group (DCCG) database. This national cancer registry includes at least 95% of all patients diagnosed with colorectal cancer in Denmark and has recently been validated, with an overall data accuracy > 95%.23

Patients undergoing a potentially curative oncological resection for a single colorectal cancer were included in the study cohort. Patients with synchronous colorectal cancers and those undergoing palliative operations, stents, or local excisions were excluded. Patients also were excluded if MMR status had not been pathologically assessed. Clinicopathological variables were extracted directly from the DCCG database. Patients were stratified into two groups according to MMR status (deficient [dMMR] or proficient [pMMR]). These groups were further subdivided according to tumor location into right colon (cecum, ascending colon, hepatic flexure, transverse colon), left colon (splenic flexure, descending colon, sigmoid colon) and rectum, and according to margin status (R0, R1tumor, R1LNM).

The original pathology assessments from each centre were used for these stratifications. Mismatch repair status was determined by immunohistochemical analysis of the four mismatch repair proteins, MLH1, PMS2, MSH2, and MSH6. Cancers lacking expression of any of these proteins were classified as dMMR. Margin status was defined according to national guidelines by inking of the nonperitonealized radial margins before sectioning of the specimen. R1 resections were defined as the presence of viable cancer cells ≤ 1 mm from the resection margin. These resections were then further divided into those ≤ 1 mm from the primary tumor (R1tumor) and those ≤ 1 mm from a metastatic lymph node or tumor deposit (R1LNM). R0 resections were defined as the absence of viable cancer cells ≤ 1 mm from the resection margin.

The primary outcome of this study was the proportion of dMMR cancers according to margin status (R0 vs. R1tumor vs. R1LNM). Secondary outcomes included overall survival (OS), defined as the time from surgery to the time of death or point of last follow-up, and the association of both MMR and margin status with OS. This study was approved by the Danish Patient Safety Authority (R-20061154) and the Danish Data Protection Agency (P-2020-902).

Univariable analyses of the differences in clinicopathological variables according to MMR status were performed by using the chi-square test for categorical data and the Mann-Whitney-Wilcoxon test for continuous data. All analyses were two-sided and were considered statistically significant with a p-value < 0.05. Overall survival was calculated by using the Kaplan-Meier method and compared by using the log-rank test. Univariable and multivariable Cox regression analyses were performed to identify prognostic factors for OS. The following factors were selected for these analyses a priori: age, tumor location, pT stage, pN stage, extramural venous invasion (EMVI), lymphatic invasion, perineural invasion, MMR status, and margin status. The results of the Cox regression analyses are presented as hazard ratios (HR) with 95% confidence interval (CI). All analyses were performed by using SPSS version 25.0 (IBM, Armonk, NY).

Results

Cohort Demographics

The study cohort comprised at total of 3636 patients with Stage III colorectal cancers (Fig. 1). The demographics of the study cohort are summarized in Table 1. The cohort included 1978 males (54.4%), and the median age was 71 years (interquartile range [IQR] 63–77 years). The median follow-up for the entire cohort was 37 months (IQR 25–51 months). A total of 473 patients (13.0%) had dMMR cancers. Compared with patients with pMMR cancers, these patients were more likely to be older and female. dMMR cancers were significantly more common in the right colon (419, 88.6%) than the left colon (41, 8.7%) and rectum (13, 2.7%, p < 0.001). Although an association with more advanced pT stage was seen in patients with dMMR cancers (89.3% ≥ pT3 vs. 81.8% in pMMR cancers, p < 0.001), no differences in pN staging (pN1a – 2b) were noted. dMMR status also was more commonly seen in poorly differentiated and mucinous adenocarcinomas and in cancers with lymphatic invasion. There was no evidence that the types of surgical procedures differed between patients with dMMR and pMMR cancers. Emergency operations were performed in 256 patients (7.0%), with no difference in the rate of emergency operations noted according to MMR status (dMMR 6.8% [32 patients] vs. pMMR 7.1% [224 patients], p = 0.802). Similarly, no difference in the rate of compromised resections, whereby a less extensive resection was performed due to patient comorbidities, was noted according to MMR status (dMMR 1.7% [8 patients] vs. pMMR 1.2% [37 patients], p = 0.339).Fig. 1 CONSORT diagram of the study cohort. MMR mismatch repair status; dMMR deficient MMR; pMMR proficient MMR

Table 1 Clinicopathological demographics according to margin status in 3636 patients with Stage III colorectal cancer

	MMR status		
pMMR	dMMR	
No. patients	3163	473	–	
Median age (IQR)	70 (62-77)	74 (68-81)	< 0.001	
Male:female	1.4	0.5	< 0.001	
Tumor location	Right colon	1067 (33.7)	419 (88.6)	< 0.001	
Left colon	1110 (35.1)	41 (8.7)	
Rectum	986 (31.2)	13 (2.7)	
Margin status	R0	2682 (84.8)	376 (79.5)	< 0.001	
R1tumour	148 (4.7)	42 (8.9)	
R1LNM	333 (10.5)	55 (11.6)	
pT stage	1	180 (5.6)	13 (2.7)	< 0.001	
2	400 (12.6)	38 (8.0)	
3	1841 (58.2)	285 (60.3)	
4	742 (23.4)	137 (29.0)	
pN stage	1a	1039 (32.8)	172 (36.4)	0.464	
1b	952 (30.1)	127 (26.8)	
1c	165 (5.2)	21 (4.4)	
2a	580 (18.3)	90 (19.0)	
2b	427 (13.5)	63 (13.3)	
Histological subtype	ADC	2662 (84.2)	178 (37.6)	< 0.001	
Poor diff ADC	144 (4.6)	137 (29.0)	
Mucinous	245 (7.8)	110 (23.3)	
Signet cell	28 (0.9)	18 (3.8)	
Other	84 (2.7)	30 (6.3)	
Extramural venous invasion	1435 (45.4)	161 (34.0)	< 0.001	
Lymphatic invasion	750 (23.7)	149 (31.5)	< 0.001	
Perineural invasion	863 (27.3)	84 (17.8)	< 0.001	
Bold values indicate statistically significant

Numbers in parentheses are percentages unless otherwise specified

MMR Mismatch repair; pMMR Proficient mismatch repair; dMMR Deficient mismatch repair; IQR Interquartile range; R0 Microscopically negative margins; R1tumor microscopically positive margins to the primary tumor; R1LNM microscopically positive margins to lymph node metastases; ADC adenocarcinoma

Association Between Margin Status and MMR Status

When considering the whole cohort, R1 resection margins were found in 15.9% of patients, with R1tumor margins found in 5.2% and R1LNM margins found in 10.7%. The rate of R1 margins was significantly higher in patients with dMMR cancers compared with those with pMMR cancers (20.5% vs. 15.2%, p < 0.001), with the greatest difference seen in the rate of R1tumor margins (8.9% vs. 4.7%). Given that both margin status and MMR status varied according to tumor location, further subgroup analyses according to tumor location were performed (Table 2). These demonstrated significantly higher rates of R1tumor margins in dMMR cancers in both right- (8.1% vs. 4.5%) and left-sided colon cancers (19.5% vs. 3.0%) compared with pMMR cancers. No association was seen in patients with rectum cancers, although only 13 of these patients had dMMR cancers.Table 2 Proportion of patients with dMMR cancers according to margin status and tumor location

	MMR	p	
pMMR	dMMR	
Right colon	R0	865 (81.1)	335 (80.0)	0.014	
R1tumor	48 (4.5)	34 (8.1)	
R1LNM	154 (14.4)	50 (11.9)	
Left colon	R0	1005 (90.5)	30 (73.1)	< 0.001	
R1tumor	33 (3.0)	8 (19.5)	
R1LNM	72 (6.5)	3 (7.3)	
Rectum	R0	812 (81.3)	11 (1.1)	0.568	
R1tumor	67 (6.7)	0 (0)	
R1LNM	107 (10.7)	2 (0.2)	
Bold values indicate statistically significant

Numbers in parentheses are percentages unless otherwise specified

MMR Mismatch repair; pMMR Proficient mismatch repair; dMMR Deficient mismatch repair; R0 Microscopically negative margins; R1tumor microscopically positive margins to the primary tumor; R1LNM microscopically positive margins to lymph node metastases

To investigate whether the rates of R1 resection margins differed between patients with sporadic or Lynch-associated dMMR cancers, subgroup analyses of patients with dMMR cancers were performed. The group was divided according to age (< 75 years [239 patients] vs. ≥ 75 years [234 patients]), because sporadic dMMR cancers are more common in elderly patients.24 No difference in the rate of R1 resection margins were noted in these subgroup analyses (< 75 years 19.7% vs. ≥ 75 years 21.4%, p = 0.647), with similar rates of R1tumor (7.9% vs. 9.8%) and R1LNM margins (11.7% vs. 11.5%) in each group.

Association Between MMR Status and Survival

When considering the whole cohort, patients with pMMR cancers had significantly better overall survival (OS) compared with those with dMMR cancers (3-year OS 79.7% [95% CI 78.9–80.5] vs. 75.3% [95% CI 73.2–77.4], p = 0.023) (Fig. 2). However, when stratified according to tumor location, the association with pMMR status and improved OS was only seen in patients with left-sided colon cancers (3-year OS 84.5% [95% CI 83.4–85.6] vs. 69.9% [95% CI 61.5–78.3], p = 0.029) and not in those with right-sided colon cancers (3-year OS 72.9% [95% CI 71.5–74.3] vs. 75.8% [95% CI 73.6–78.0], p = 0.246) (Fig. 3). The effect of margin status on survival outcomes in patients with pMMR (Fig. 4a) and dMMR (Fig. 4b) cancers also was investigated. In both groups, R1 margins were associated with significant reductions in 3-year OS compared with R0 margins, with the worst outcomes seen in patients with R1tumor margins. In patients with R1tumor margins, no difference was noted in survival between patients with dMMR or pMMR cancers (3-year OS 51.0% [95% CI 43.1–58.9] vs. 54.9% [95% CI 50.5–59.3], p = 0.388). Following multivariable analysis, no significant association between MMR status and OS was identified (Table 3). Age, pN stage, EMVI, perineural invasion, and R1 margins were associated with poorer OS, whereas left-sided cancers were associated with improved OS.Fig. 2 Overall survival (OS) stratified according to mismatch repair (MMR) status. The blue line represents patients with pMMR cancers (3-year OS 79.7% [95% CI 78.9–80.5]). The red line represents patients with dMMR cancers (3-year OS 75.3% [95% CI 73.2–77.4], p = 0.023).

Fig. 3 Overall survival (OS) stratified according to mismatch repair (MMR) status and tumor location. A Right-sided colon cancers—3-year OS in patients with pMMR cancers (blue line) 72.9% (95% CI 71.5–74.3) versus dMMR cancers (red line) 75.8% (95% CI 73.6–78.0), p = 0.246. B Left-sided colon cancers—3-year OS in patients with pMMR cancers (blue line) 84.5% (95% CI 83.4–85.6) versus dMMR cancers (red line) 69.9% (95% CI 61.5–78.3), p = 0.029. C Rectum cancers—3-year OS in patients with pMMR cancers (blue line) 81.7% (95% CI 80.4–83.0) versus dMMR cancers (red line) 75.2% (95% CI 62.6–87.6), p = 0.598

Fig. 4 A Overall survival (OS) in patients with pMMR cancers. Three-year OS in those with R0 margins (blue line, 82.4% [95% CI 81.6–83.2]), R1tumor margins (green line, 56.0% [95% CI 51.6–60.4]) and R1LNM margins (red line, 69.3% [95% CI 66.7–71.9]). B Overall survival (OS) in patients with dMMR cancers. Three-year OS in those with R0 margins (blue line, 79.5% [95% CI 77.3–81.7]), R1tumor margins (green line, 51.0% [95% CI 43.1–58.9]) and R1LNM margins (red line, 65.2% [95% CI 58.1–72.3])

Table 3 Univariable and multivariable analyses of prognostic factors for overall survival

	HR (95% CI)	p	HR (95% CI)	p	
Age	1.07 (1.06-1.08)	<0.001	1.07 (1.06-1.08)	<0.001	
Tumor location	Right	Reference	–	Reference	–	
Left	0.57 (0.48-0.67)	<0.001	0.70 (0.57-0.87)	0.001	
Rectum	0.65 (0.55-0.77)	<0.001	0.94 (0.76-1.16)	0.581	
T stage	1	Reference	–	Reference	–	
2	1.40 (0.83-2.35)	0.202	0.85 (0.47-1.53)	0.590	
3	2.21 (1.39-3.49)	<0.001	0.86 (0.52-1.45)	0.577	
4	4.68 (2.95-7.44)	<0.001	1.39 (0.81-2.37)	0.230	
N stage	1a	Reference	–	Reference	–	
1b	1.14 (0.94-1.38)	0.174	1.00 (0.79-1.26)	0.983	
1c	1.30 (0.91-1.85)	0.145	1.01 (0.70-1.45)	0.976	
2a	1.61 (1.32-1.96)	<0.001	1.38 (1.08-1.77)	0.011	
2b	2.70 (2.22-3.28)	<0.001	1.77 (1.37-2.29)	<0.001	
EMVI	2.05 (1.79-2.36)	<0.001	1.38 (1.15-1.66)	<0.001	
Lymphatic invasion	1.58 (1.34-1.86)	<0.001	*	*	
Perineural invasion	1.87 (1.62-2.16)	<0.001	1.43 (1.19-1.72)	<0.001	
MMR	pMMR	Reference	–	Reference	–	
dMMR	1.24 (1.03-1.51)	0.023	*	*	
Margins	R0	Reference	–	Reference	–	
R1tumour	2.86 (2.29-3.59)	<0.001	2.16 (1.65-2.83)	<0.001	
R1LNM	1.97 (1.64-2.38)	<0.001	1.47 (1.16-1.86)	0.001	
Bold values indicate statistically significant

EMVI Extramural venous invasion; MMR Mismatch repair; pMMR Proficient mismatch repair; dMMR Deficient mismatch repair; R0 Microscopically negative margins; R1tumor Microscopically positive margins to the primary tumor; R1LNM Microscopically positive margins to lymph node metastases

Discussion

To the authors’ knowledge, this is the first study to investigate the association between MMR status and R1 resection margins in patients with Stage III colorectal cancers. We found that patients with dMMR cancers have significantly higher rates of R1tumor margins following potentially curative surgery and that this association is seen in both patients with right- or left-sided colon cancers. These findings should have a substantial clinical impact. The association with R1 margins and poorer oncological outcomes has long been recognized in patients with rectum cancers.2–5 However, recent studies have highlighted that R1 margins occur just as frequently in patients with colon cancer.6–8 These studies demonstrate a consistent association between R1 margins and increased risks of systemic relapse and death in these patients. Recent studies by our group, using the same patient cohort as in the current study, demonstrated that these risks are greater in patients with R1tumor margins compared with those with R1LNM margins.12,13 As such, patients with R1 resections after potentially curative surgery for colon cancers should be considered a particularly high-risk group.

One possible way to address these risks would be to escalate therapy in these high-risk patients. This should ideally be in the form of neoadjuvant therapy; in a previous study, we found that the increased risks of relapse in patients with R1 resections persist even after long-course adjuvant chemotherapy.14 Although neoadjuvant chemotherapy does not yet have an established role in the treatment of colon cancers, the FOxTROT study has provided some promising results.25 In that study, patients treated with neoadjuvant oxaliplatin-fluoropyrimidine chemotherapy had a significantly lower rate of R1 resections following surgery compared with the control arm (6% vs. 11%, p < 0.001). However, FOxTROT also highlighted two potential issues with neoadjuvant chemotherapy. The first lies in patient selection. Clinical staging for colon cancer has limited accuracy.26 By using clinical staging to allocate “high-risk” patients to neoadjuvant chemotherapy, FOxTROT was associated with significant risks of overtreatment, whereby 24% of patients in the control arm were found to have Stage I or low-risk Stage II cancers. Similar risks of overtreatment were seen in the PRODIGE 22 study.27 So, whilst neoadjuvant chemotherapy may be of some benefit in patients with colon cancer, identifying which patients are at high-risk before surgery is challenging. This is even more true for patients with R1 margins, a characteristic that by definition is only known after surgery.

The second issue with neoadjuvant chemotherapy is that it appears only to be of benefit in patients with pMMR rather than dMMR cancers.25 Fortunately, contrasting results have been shown in early trials of neoadjuvant immunotherapy. In the NICHE study, a single dose of ipilimumab and two doses of pembrolizumab resulted in major pathological responses in 95% of patients with dMMR cancers compared with 20% of patients with pMMR cancers.20 Similarly impressive results have been seen in patients with dMMR rectal cancers, where in an early clinical trial of 9 cycles of treatment with dostarlimab resulted in clinical complete responses in all patients, obviating the need for further treatment.19 Although these results need to be confirmed in larger trials, the exquisite sensitivity of dMMR colorectal cancer to immune checkpoint blockade has already led many to question whether surgery is still necessary in the majority of these patients. Whilst this remains to be seen, what is undoubtable is that neoadjuvant immunotherapy offers a clear opportunity to avoid R1 resections in patients with dMMR cancers, who can easily be identified by preoperative immunohistochemical/molecular analyses of diagnostic biopsies. Based on the proportion of patients with dMMR cancers in the current study, such a strategy would reduce the total number of R1 resections in patients with Stage III colorectal cancer by > 15%.

Despite its association with R1 resections, dMMR status was not found to be independently associated with survival in the current study. While this may seem paradoxical, there have been conflicting reports about the prognostic value of dMMR in previous studies. In general, dMMR cancers have an association with an earlier stage of disease at the time of diagnosis compared with pMMR cancers.28 Furthermore, in patients with Stage II disease, there is robust evidence that dMMR cancers are associated with reduced risks of relapse and improved survival.29 However, in patients with Stage III disease, two meta-analyses have found contrasting results and any association with survival outcomes is less certain.30,31 Finally, in patients with metastatic disease, dMMR status actually appears to be associated with poorer oncological outcomes.32 The reason for these contrasting associations with survival is not entirely clear. Given the association of dMMR status with increased immune infiltration of the primary tumour, one hypothesis is that stage progression is associated with exhaustion of any antitumor immune responses, annulling the prognostic advantages seen in earlier-stage disease.33,34

The authors recognise the limitations of this study. In Denmark, MMR status is determined by using immunohistochemistry. Other molecular assessments, such as for BRAF mutations, are not mandatory during the initial diagnostic workup. As such, it was not possible to divide the patients in the current study into those with sporadic dMMR cancers and those with hereditary dMMR cancers associated with Lynch syndrome. Significant differences have been demonstrated between these groups, whereby sporadic dMMR cancers are more common, more likely to occur in elderly patients and are associated with poorer survival.24 As such it would have been of interest to investigate whether the association with R1 margins is seen in both dMMR subgroups. The subgroup analyses performed in the current study were based on an arbitrary age cutoff of 75 years, as the majority of patients diagnosed with dMMR cancers over this age have sporadic cancers. While these analyses did not find any differences in the rate of R1 margins between these groups, these results should be interpreted with caution. A more robust approach would have been to compare outcomes between sporadic and hereditary dMMR cancers defined by molecular assessments. A further limitation is that whilst survival data was available for these patients, corresponding data regarding both local and distant recurrence was not available. Although one may argue that survival is the most relevant endpoint in these patients, it would have been of interest to investigate the impact of MMR status on disease recurrence as well.

Conclusions

In patients with Stage III colon cancers, dMMR status is associated with a significantly higher risk of R1tumor margins following potentially curative surgery. This adds a further rationale for the use of neoadjuvant immunotherapy in this patient group.

Funding

Open access funding provided by Copenhagen University. None to declare.

Disclosure

The authors declare that they no conflict of interest.

Ethical approval

This study was approved by the Danish Patient Safety Authority (R-20061154) and the Danish Data Protection Agency (P-2020-902).

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Loughrey MB Webster F Arends MJ Brown I Burgart LJ Cunningham C Dataset for pathology reporting of colorectal cancer: recommendations from the international collaboration on cancer reporting (ICCR) Ann Surg. 2022 275 3 e549 e561 10.1097/SLA.0000000000005051 34238814
Loughrey MB, Webster F, Arends MJ, Brown I, Burgart LJ, Cunningham C, et al. Dataset for pathology reporting of colorectal cancer: recommendations from the international collaboration on cancer reporting (ICCR). Ann Surg. 2022;275(3):e549–61.34238814
2. Bernstein TE, Endreseth BH, Romundstad P, Wibe A, Norwegian Colorectal Cancer G. Circumferential resection margin as a prognostic factor in rectal cancer. Br J Surg. 2009;96(11):1348-57.
3. Birbeck KF Macklin CP Tiffin NJ Parsons W Dixon MF Mapstone NP Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery Ann Surg. 2002 235 4 449 457 10.1097/00000658-200204000-00001 11923599
Birbeck KF, Macklin CP, Tiffin NJ, Parsons W, Dixon MF, Mapstone NP, et al. Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg. 2002;235(4):449–57.11923599
4. Nagtegaal ID Marijnen CA Kranenbarg EK van de Velde CJ van Krieken JH Pathology Review C Cooperative Clinical I Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit Am J Surg Pathol. 2002 26 3 350 357 10.1097/00000478-200203000-00009 11859207
Nagtegaal ID, Marijnen CA, Kranenbarg EK, van de Velde CJ, van Krieken JH, Pathology Review C, Cooperative Clinical I. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol. 2002;26(3):350–7.11859207
5. Wibe A Rendedal PR Svensson E Norstein J Eide TJ Myrvold HE Soreide O Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer Br J Surg. 2002 89 3 327 334 10.1046/j.0007-1323.2001.02024.x 11872058
Wibe A, Rendedal PR, Svensson E, Norstein J, Eide TJ, Myrvold HE, Soreide O. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg. 2002;89(3):327–34.11872058
6. Amri R Bordeianou LG Sylla P Berger DL Association of radial margin positivity with colon cancer JAMA Surg. 2015 150 9 890 898 10.1001/jamasurg.2015.1525 26132363
Amri R, Bordeianou LG, Sylla P, Berger DL. Association of radial margin positivity with colon cancer. JAMA Surg. 2015;150(9):890–8.26132363
7. Healy MA Peacock O Hu CY Bednarski BK Tillman MM Messick C High rate of positive circumferential resection margin in colon cancer: a national appraisal and call for action Ann Surg. 2022 276 6 1023 1028 10.1097/SLA.0000000000004682 33630474
Healy MA, Peacock O, Hu CY, Bednarski BK, Tillman MM, Messick C, et al. High rate of positive circumferential resection margin in colon cancer: a national appraisal and call for action. Ann Surg. 2022;276(6):1023–8.33630474
8. Khan MA Hakeem AR Scott N Saunders RN Significance of R1 resection margin in colon cancer resections in the modern era Colorectal Dis. 2015 17 11 943 953 10.1111/codi.12960 25808496
Khan MA, Hakeem AR, Scott N, Saunders RN. Significance of R1 resection margin in colon cancer resections in the modern era. Colorectal Dis. 2015;17(11):943–53.25808496
9. Hall NR Finan PJ Al-Jaberi T Tsang CS Brown SR Dixon MF Quirke P Circumferential margin involvement after mesorectal excision of rectal cancer with curative intent. Predictor of survival but not local recurrence? Dis Colon Rectum. 1998 41 8 979 983 10.1007/BF02237384 9715152
Hall NR, Finan PJ, Al-Jaberi T, Tsang CS, Brown SR, Dixon MF, Quirke P. Circumferential margin involvement after mesorectal excision of rectal cancer with curative intent. Predictor of survival but not local recurrence? Dis Colon Rectum. 1998;41(8):979–83.9715152
10. Nagtegaal ID Quirke P What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008 26 2 303 312 10.1200/JCO.2007.12.7027 18182672
Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008;26(2):303–12.18182672
11. Smith HG Chiranth DJ Schlesinger NH Do differences in surgical quality account for the higher rate of R1 margins to lymph node metastases in right- versus left-sided Stage III colon cancer: a retrospective cohort study Colorectal Dis. 2023 25 4 679 687 10.1111/codi.16459 36565048
Smith HG, Chiranth DJ, Schlesinger NH. Do differences in surgical quality account for the higher rate of R1 margins to lymph node metastases in right- versus left-sided Stage III colon cancer: a retrospective cohort study. Colorectal Dis. 2023;25(4):679–87.36565048
12. Smith HG Chiranth D Mortensen CE Schlesinger NH The significance of subdivisions of microscopically positive (R1) margins in colorectal cancer: a retrospective study of a national cancer registry Colorectal Dis. 2022 24 2 197 209 10.1111/codi.15971 34714581
Smith HG, Chiranth D, Mortensen CE, Schlesinger NH. The significance of subdivisions of microscopically positive (R1) margins in colorectal cancer: a retrospective study of a national cancer registry. Colorectal Dis. 2022;24(2):197–209.34714581
13. Smith HG Skovgaards DM Chiranth D Schlesinger NH The impact of subdivisions of microscopically positive (R1) margins on patterns of relapse in stage III colorectal cancer—a retrospective cohort study Colorectal Dis. 2022 24 7 828 837 10.1111/codi.16121 35304974
Smith HG, Skovgaards DM, Chiranth D, Schlesinger NH. The impact of subdivisions of microscopically positive (R1) margins on patterns of relapse in stage III colorectal cancer—a retrospective cohort study. Colorectal Dis. 2022;24(7):828–37.35304974
14. Smith HG Skovgaards DM Bui NH Chiranth D Qvortrup C Schlesinger NH Differences in adjuvant chemotherapy and oncological outcomes according to margin status in patients with stage III colon cancer Acta Oncol. 2023 62 6 594 600 10.1080/0284186X.2023.2218555 37265367
Smith HG, Skovgaards DM, Bui NH, Chiranth D, Qvortrup C, Schlesinger NH. Differences in adjuvant chemotherapy and oncological outcomes according to margin status in patients with stage III colon cancer. Acta Oncol. 2023;62(6):594–600.37265367
15. Peltomaki P Role of DNA mismatch repair defects in the pathogenesis of human cancer J Clin Oncol. 2003 21 6 1174 1179 10.1200/JCO.2003.04.060 12637487
Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol. 2003;21(6):1174–9.12637487
16. Popat S Hubner R Houlston RS Systematic review of microsatellite instability and colorectal cancer prognosis J Clin Oncol. 2005 23 3 609 618 10.1200/JCO.2005.01.086 15659508
Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609–18.15659508
17. Sargent DJ Marsoni S Monges G Thibodeau SN Labianca R Hamilton SR Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer J Clin Oncol. 2010 28 20 3219 3226 10.1200/JCO.2009.27.1825 20498393
Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–26.20498393
18. Argiles G Tabernero J Labianca R Hochhauser D Salazar R Iveson T Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol. 2020 31 10 1291 1305 10.1016/j.annonc.2020.06.022 32702383
Argiles G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291–305.32702383
19. Cercek A Lumish M Sinopoli J Weiss J Shia J Lamendola-Essel M PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer N Engl J Med. 2022 386 25 2363 2376 10.1056/NEJMoa2201445 35660797
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386(25):2363–76.35660797
20. Chalabi M Fanchi LF Dijkstra KK Van den Berg JG Aalbers AG Sikorska K Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers Nat Med. 2020 26 4 566 576 10.1038/s41591-020-0805-8 32251400
Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566–76.32251400
21. Le DT Uram JN Wang H Bartlett BR Kemberling H Eyring AD PD-1 Blockade in Tumors with Mismatch-Repair Deficiency N Engl J Med. 2015 372 26 2509 2520 10.1056/NEJMoa1500596 26028255
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509–20.26028255
22. von Elm E Altman DG Egger M Pocock SJ Gotzsche PC Vandenbroucke JP Initiative S The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies J Clin Epidemiol. 2008 61 4 344 349 10.1016/j.jclinepi.2007.11.008 18313558
von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative S. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–9.18313558
23. Klein MF, Gogenur I, Ingeholm P, Njor SH, Iversen LH, Emmertsen KJ, Group DV Validation of the danish colorectal cancer group (DCCG.dk) database - on behalf of the Danish Colorectal Cancer Group Colorectal Dis. 2020 22 12 2057 2067 10.1111/codi.15352 32894818
Klein MF, Gogenur I, Ingeholm P, Njor SH, Iversen LH, Emmertsen KJ, Group DV. Validation of the danish colorectal cancer group (DCCG.dk) database - on behalf of the Danish Colorectal Cancer Group. Colorectal Dis. 2020;22(12):2057–67.32894818
24. Liu GC Liu RY Yan JP An X Jiang W Ling YH The heterogeneity between lynch-associated and sporadic MMR deficiency in colorectal cancers J Natl Cancer Inst. 2018 110 9 975 984 10.1093/jnci/djy004 29471527
Liu GC, Liu RY, Yan JP, An X, Jiang W, Ling YH, et al. The heterogeneity between lynch-associated and sporadic MMR deficiency in colorectal cancers. J Natl Cancer Inst. 2018;110(9):975–84.29471527
25. Morton D Seymour M Magill L Handley K Glasbey J Glimelius B Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial J Clin Oncol. 2023 41 8 1541 1552 10.1200/JCO.22.00046 36657089
Morton D, Seymour M, Magill L, Handley K, Glasbey J, Glimelius B, et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol. 2023;41(8):1541–52.36657089
26. Malmstrom ML Brisling S Klausen TW Saftoiu A Perner T Vilmann P Gogenur I Staging with computed tomography of patients with colon cancer Int J Colorectal Dis. 2018 33 1 9 17 10.1007/s00384-017-2932-3 29116438
Malmstrom ML, Brisling S, Klausen TW, Saftoiu A, Perner T, Vilmann P, Gogenur I. Staging with computed tomography of patients with colon cancer. Int J Colorectal Dis. 2018;33(1):9–17.29116438
27. Karoui M Rullier A Piessen G Legoux JL Barbier E De Chaisemartin C Perioperative FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a phase II multicenter randomized controlled trial (PRODIGE 22) Ann Surg. 2020 271 4 637 645 10.1097/SLA.0000000000003454 31356278
Karoui M, Rullier A, Piessen G, Legoux JL, Barbier E, De Chaisemartin C, et al. Perioperative FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a phase II multicenter randomized controlled trial (PRODIGE 22). Ann Surg. 2020;271(4):637–45.31356278
28. Vinal D Martinez-Perez D Martínez-Recio S Ruiz I Jimenez Bou D Pena J Clinicopathological characteristics and outcomes of patients with deficient mismatch repair colorectal cancer J Clin Oncol. 2022 40 4_Suppl 181 10.1200/JCO.2022.40.4_suppl.181
Vinal D, Martinez-Perez D, Martínez-Recio S, Ruiz I, Jimenez Bou D, Pena J, et al. Clinicopathological characteristics and outcomes of patients with deficient mismatch repair colorectal cancer. J Clin Oncol. 2022;40(4_Suppl):181.
29. Sargent DJ Shi Q Yothers G Tejpar S Bertagnolli MM Thibodeau SN Prognostic impact of deficient mismatch repair (dMMR) in 7803 stage II/III colon cancer (CC) patients (pts): a pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database J Clin Oncol 2014 10.1200/jco.2014.32.15_suppl.3507 25385741
Sargent DJ, Shi Q, Yothers G, Tejpar S, Bertagnolli MM, Thibodeau SN, et al. Prognostic impact of deficient mismatch repair (dMMR) in 7803 stage II/III colon cancer (CC) patients (pts): a pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. J Clin Oncol. 2014. 10.1200/jco.2014.32.15_suppl.3507.25385741
30. Deng Z Qin Y Wang J Wang G Lang X Jiang J Prognostic and predictive role of DNA mismatch repair status in stage II-III colorectal cancer: a systematic review and meta-analysis Clin Genet. 2020 97 1 25 38 10.1111/cge.13628 31432497
Deng Z, Qin Y, Wang J, Wang G, Lang X, Jiang J, et al. Prognostic and predictive role of DNA mismatch repair status in stage II-III colorectal cancer: a systematic review and meta-analysis. Clin Genet. 2020;97(1):25–38.31432497
31. Wang B Li F Zhou X Ma Y Fu W Is microsatellite instability-high really a favorable prognostic factor for advanced colorectal cancer? A meta-analysis World J Surg Oncol. 2019 17 1 169 10.1186/s12957-019-1706-5 31639018
Wang B, Li F, Zhou X, Ma Y, Fu W. Is microsatellite instability-high really a favorable prognostic factor for advanced colorectal cancer? A meta-analysis. World J Surg Oncol. 2019;17(1):169.31639018
32. Venderbosch S Nagtegaal ID Maughan TS Smith CG Cheadle JP Fisher D Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies Clin Cancer Res. 2014 20 20 5322 5330 10.1158/1078-0432.CCR-14-0332 25139339
Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20(20):5322–30.25139339
33. Buckowitz A Knaebel HP Benner A Blaker H Gebert J Kienle P Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases Br J Cancer. 2005 92 9 1746 1753 10.1038/sj.bjc.6602534 15856045
Buckowitz A, Knaebel HP, Benner A, Blaker H, Gebert J, Kienle P, et al. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer. 2005;92(9):1746–53.15856045
34. Le DT Durham JN Smith KN Wang H Bartlett BR Aulakh LK Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade Science 2017 357 6349 409 413 10.1126/science.aan6733 28596308
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13.28596308
